Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVIDENS: Lung Cancer Patients Treated With Nivolumab: A Longitudinal, Prospective, Observational, Multicentric Study

Next Previous
Trial Profile

EVIDENS: Lung Cancer Patients Treated With Nivolumab: A Longitudinal, Prospective, Observational, Multicentric Study

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms EVIDENS
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 24 Oct 2023 Results from NCT03382496 and NCT02910999, describing RW survival outcomes of patients with aNSCLC who resumed nivo after interrupting an initial nivo treatment received as 2+ line-of-therapy presented at the 48th European Society for Medical Oncology Congress
    • 21 Sep 2021 Results assessing long-term overall survival (OS) and health-related quality of life (HRQoL)., presented at the 46th European Society for Medical Oncology Congress.
    • 01 Jul 2021 Results of pooled analysis of a real world patients (n=2585)from EVIDENS and ENLARGE and a retrospective registry study evaluating Two-year survival with nivolumab in previously treated advanced non small-cell lung cancer published in the Lung Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top